ClinicalTrials.gg
Not yet recruitingNCT07863869Updated Oct 19, 2026

The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases

A Phase 1/2 interventional study of Arm A and Arm B in Colorectal Cancer Metastatic to Liver, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
102
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 21 open to participants now, 22 under way, 1 of them phase 3. Colorectal Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Planned enrollment
8th of 17
102 · median 102
Started
2026
with 3 others
Phase 1/2
2 of 27
2 open now
Primary completion
2029-05
later than 20 of 21 live
Registered
25th of 27
by date

Among the 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 20 of the 21 other live ones, and was the 25th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if QL1706 (Iparomlimab/ Tuvonralimab)+ chemotherapy+ cetuximab/bevacizumab works to treat potentially resectable colorectal cancer patients with liver metastases in adults. It will also learn about the safety of this therapeutic regimen. The main questions it aims to answer are: Does QL1706+ Chemotherapy+ Cetuximab/Bevacizumab improve the 18-month progression free survival (PFS) rate of participants?

The study plans to enroll 90-102 patients, who will be divided into 2 arms based on the primary tumor location and genetic status.

Arm A: Patients with primary tumors located in the left colorectum and RAS ( Rat Sarcoma Virus ) and BRAF ( V-raf Murine Sarcoma Viral Oncogene Homolog B ) wild-type.

Arm B: Patients with primary tumors located in the right colorectum and/or RAS or BRAF mutant

The study consists of two phases: phase Ib ( safety run-in phase ) and phase II.

03

Conditions studied

  • Colorectal Cancer Metastatic to Liver
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has signed a written form and voluntarily participates in this study;
  • Age: 18-75 years old, regardless of gender;
  • or cytologically confirmed colorectal adenocarcinoma with liver , initially unresectable but potentially resectable as assessed by a multidisciplinary team (MDT), without other definite extrahepatic distant metastases;
  • No prior systemic treatment;
  • Known RAS and BRAF status;
  • No to liver surgery;
  • At least one according to 1.1;
  • performance status: 0-1;
  • Expected survival time > 12 weeks;
  • Sufficient organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  • Active diseases requiring systemic treatment occurring within 2 years before enrollment.
  • Previous receipt of , including: anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, etc.
  • Previous receipt of targeted drugs targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or their receptors (VEGFR), including bevacizumab, cetuximab, panitumumab, aflibercept, regorafenib, anlotinib, etc.
  • Definite extrahepatic distant lesions.
  • Unresectable primary tumor.
  • infection, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or bone marrow transplantation (except corneal transplantation).
  • Previous or concurrent other malignant tumors within 5 years;
  • Accompanying pleural effusion, pericardial effusion, or ascites that is uncontrollable and requires drainage.
  • Known active pulmonary tuberculosis, radiation pneumonitis, drug-induced pneumonia, or other diseases, symptoms, or signs causing severe impairment of lung function.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Arm A ( QL1706 Combined with mFOLFOX6 and Cetuximab )

    Participants with primary tumors located in the left colorectum and RAS and BRAF wild-type will receive QL1706 Combined with mFOLFOX6 and Cetuximab

    Drug: Arm A

  • Experimental
    Arm B ( QL1706 Combined with FOLFOXIRI and Bevacizumab )

    Participants with primary tumors located in the right colorectum and/or RAS or BRAF mutant will receive QL1706 Combined with FOLFOXIRI and Bevacizumab

    Drug: Arm B

Interventions

  • DrugArm A

    QL1706 3mg/kg, IV, D1, Q2W, for a maximum of 2 years. mFOLFOX6 : Oxaliplatin 85 mg/m², IV, D1, Q2W, for a maximum of 12 cycles. LV 400mg/m², IV, D1, Q2W, for a maximum of 2 years. 5-FU 400mg/m², IV, D1; followed by a continuous intravenous infusion of 1200mg/(m²•d) for 2 days (total dose 2400mg/m², infusion duration 46-48 hours), Q2W, for a maximum of 2 years. Cetuximab 500mg/m², IV, D1, Q2W, for a maximum of 2 years.

  • DrugArm B

    QL1706 3mg/kg, IV, D1, Q2W, for a maximum of 2 years FOLFOXIRI : Irinotecan 150mg/m², IV, D1, Q2W, for a maximum of 12 cycles Oxaliplatin 85mg/m², IV, D1, Q2W, for a maximum of 12 cycles LV 400mg/m², IV, D1, Q2W, for a maximum of 2 years 5-FU (total dose: 2400mg/m²) via continuous intravenous infusion for 48 hours, D1, Q2W, for a maximum of 2 years Bevacizumab 5mg/kg, IV, D1, Q2W, for a maximum of 2 years

06

What researchers measure

Primary outcomes

  1. 18-month Progression-Free Survival (PFS) rate in phase II

    18-month PFS rate is defined as the proportion of participants who are alive and progression free at 18 months from start of study treatment. Assessed according to RECIST v1.1 by investigator.

    Time frame: From enrollment to 18 months after enrollment

  2. safety in phase Ib

    Determine frequency and severity of adverse events as assessed by NCI-CTCAE v5.0

    Time frame: From enrollment to 18 months after enrollment

Secondary outcomes

  1. R0/R1 resection rate

    Time frame: From enrollment to 18 months after enrollment

  2. Objective Response Rate (ORR)

    Time frame: From enrollment to 18 months after enrollment

  3. Progression-Free Survival (PFS)

    Time frame: From enrollment to 18 months after enrollment

  4. Time to Response (TTR)

    Time frame: From enrollment to 18 months after enrollment

  5. Disease Control Rate (DCR)

    Time frame: From enrollment to 18 months after enrollment

  6. 18-Month/24-Month No Evidence of Disease (NED) Rate

    Time frame: From enrollment to 24 months after enrollment

  7. Adverse Event

    Time frame: From enrollment to 24 months after enrollment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2029, 32 months later.

Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 32 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Oct 7, 2026
StartEst.
Sep 2026
Primary completionEst.
May 27, 2029
CompletionEst.
Nov 27, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 2 updates
  1. Oct 19, 2026
    Minor edits only
    + 1 other change: identifiers
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863869
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Sep 2026 (estimated)
Primary completion
May 27, 2029 (estimated)
Completion
Nov 27, 2029 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion